EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB

Reuters

09/10

EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB

EUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566049966"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566049966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566049966?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566049966","market":"fut","top_or_hot":-1,"title":"EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EUDA\">EUDA Health Holdings Limited</a>, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/EUDAW\">Euda Health</a> Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-10 21:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EUDA\">EUDA Health Holdings Limited</a>, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/EUDAW\">Euda Health</a> Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL7mf7Nw:1","article_id":"2566049966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566049966","pubTimestamp":1757511019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"EUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell  solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4196":"保健护理服务","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","EUDA":"EUDA Health Holdings Limited"},"translate_title":"EUDA Health Holdings Ltd.签署收购新加坡生物技术公司GO POSB的意向书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EUDA":0.9,"NDAQ":0.9},"content_text":"EUDA Health Holdings Ltd. Signs Letter of Intent to Acquire Singapore-Based Biotechnology Firm GO POSB\n    \n\nEUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider, announced through a press release that its subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore. The intended acquisition aims to enhance EUDA's capabilities in supplying B2B induced pluripotent stem cell (iPSC) solutions to the healthcare ecosystem, including hospitals and regenerative clinics. The collaboration plans to establish an iPSC laboratory and cultivation facility in Shenzhen, China, to support iPSC research and applications. GO POSB has developed a platform that reprograms human blood cells into therapeutics-ready stem cells, promising advancements in drug discovery and regenerative medicine without ethical concerns associated with embryonic stem cells.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526730-en) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}